Structural Biology of Flavivirus NS1 Protein and Its Antibody Complexes
Antiviral Res. 2024 May 20:105915. doi: 10.1016/j.antiviral.2024.105915. Online ahead of print.ABSTRACTThe genus of flavivirus includes many mosquito-borne human pathogens, such as Zika (ZIKV) and the four serotypes of dengue (DENV1-4) viruses, that affect billions of people as evidenced by epidemics and endemicity in many countries and regions in the world. Among the 10 viral proteins encoded by the viral genome, the nonstructural protein 1 (NS1) is the only secreted protein and has been used as a diagnostic biomarker. NS1 has also been an attractive target for its biotherapeutic potential as a vaccine antigen. This revie...
Source: Antiviral Research - May 22, 2024 Category: Virology Authors: Bing Liang Alvin Chew Qi Pan Hongli Hu Dahai Luo Source Type: research

6-Thioguanine inhibits severe fever with thrombocytopenia syndrome virus through suppression of EGR1
In conclusion, we have identified 6-TG as an effective inhibitor of SFTSV replication via the inhibition of EGR1 expression. Further studies are needed to evaluate of 6-TG as a potential therapeutic for treating SFTS.PMID:38777095 | DOI:10.1016/j.antiviral.2024.105916 (Source: Antiviral Research)
Source: Antiviral Research - May 22, 2024 Category: Virology Authors: Na Jiang Yating He Jing Wu Qiao You Rui Zhang Min Cheng Bingxin Liu Yurong Cai Ruining Lyu Zhiwei Wu Source Type: research

JNJ-7184, a Respiratory Syncytial Virus inhibitor targeting the connector domain of the viral polymerase
Antiviral Res. 2024 May 19:105907. doi: 10.1016/j.antiviral.2024.105907. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) can cause pulmonary complications in infants, elderly and immunocompromised patients. While two vaccines and two prophylactic monoclonal antibodies are now available, treatment options are still needed. JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, displaying potent inhibition of both RSV-A and -B strains. Resistance selection and hydrogen-deuterium exchange experiments suggested JNJ-7184 binds RSV-L in the connector domain. JNJ-7184 prevented RSV replication and...
Source: Antiviral Research - May 21, 2024 Category: Virology Authors: Brecht Bonneux Afzaal Shareef Sergey Tcherniuk Brandon Anson Suzanne de Bruyn Nick Verheyen Kim Thys N ádia Conceição-Neto Marcia Van Ginderen Leen Kwanten Nina Ysebaert Luc Vranckx Elien Peeters Ellen Lanckacker Jack M Gallup Panchan Sitthicharoenchai Source Type: research

Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice
Antiviral Res. 2024 May 15;227:105914. doi: 10.1016/j.antiviral.2024.105914. Online ahead of print.ABSTRACTDue to the severity of CMV infection in immunocompromised individuals the development of a vaccine has been declared a priority. However, despite the efforts made there is no yet a vaccine available for clinical use. We designed an approach to identify new CMV antigens able to inducing a broad immune response that could be used in future vaccine formulations. We have used serum samples from 28 kidney transplant recipients, with a previously acquired CMV-specific immune response to identify viral proteins that were rec...
Source: Antiviral Research - May 17, 2024 Category: Virology Authors: Francisco J Mancebo Marcos Nu évalos Jaanam Lalchandani Antonio J Mart ín Galiano Mario Fern ández-Ruiz Jos é María Aguado Est éfani García-Ríos Pilar P érez-Romero Source Type: research

Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice
Antiviral Res. 2024 May 15;227:105914. doi: 10.1016/j.antiviral.2024.105914. Online ahead of print.ABSTRACTDue to the severity of CMV infection in immunocompromised individuals the development of a vaccine has been declared a priority. However, despite the efforts made there is no yet a vaccine available for clinical use. We designed an approach to identify new CMV antigens able to inducing a broad immune response that could be used in future vaccine formulations. We have used serum samples from 28 kidney transplant recipients, with a previously acquired CMV-specific immune response to identify viral proteins that were rec...
Source: Antiviral Research - May 17, 2024 Category: Virology Authors: Francisco J Mancebo Marcos Nu évalos Jaanam Lalchandani Antonio J Mart ín Galiano Mario Fern ández-Ruiz Jos é María Aguado Est éfani García-Ríos Pilar P érez-Romero Source Type: research

Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice
Antiviral Res. 2024 May 15;227:105914. doi: 10.1016/j.antiviral.2024.105914. Online ahead of print.ABSTRACTDue to the severity of CMV infection in immunocompromised individuals the development of a vaccine has been declared a priority. However, despite the efforts made there is no yet a vaccine available for clinical use. We designed an approach to identify new CMV antigens able to inducing a broad immune response that could be used in future vaccine formulations. We have used serum samples from 28 kidney transplant recipients, with a previously acquired CMV-specific immune response to identify viral proteins that were rec...
Source: Antiviral Research - May 17, 2024 Category: Virology Authors: Francisco J Mancebo Marcos Nu évalos Jaanam Lalchandani Antonio J Mart ín Galiano Mario Fern ández-Ruiz Jos é María Aguado Est éfani García-Ríos Pilar P érez-Romero Source Type: research

Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice
Antiviral Res. 2024 May 15;227:105914. doi: 10.1016/j.antiviral.2024.105914. Online ahead of print.ABSTRACTDue to the severity of CMV infection in immunocompromised individuals the development of a vaccine has been declared a priority. However, despite the efforts made there is no yet a vaccine available for clinical use. We designed an approach to identify new CMV antigens able to inducing a broad immune response that could be used in future vaccine formulations. We have used serum samples from 28 kidney transplant recipients, with a previously acquired CMV-specific immune response to identify viral proteins that were rec...
Source: Antiviral Research - May 17, 2024 Category: Virology Authors: Francisco J Mancebo Marcos Nu évalos Jaanam Lalchandani Antonio J Mart ín Galiano Mario Fern ández-Ruiz Jos é María Aguado Est éfani García-Ríos Pilar P érez-Romero Source Type: research

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
This study demonstrates that recombinant RABV expressing tandem RBD-heterotrimer as a multivalent immunogen could elicit a broad-spectrum immune response and potent protection against SARS-CoV-2, making it a promising candidate for future human or veterinary vaccines and offering a novel perspective in other vaccine design.PMID:38740191 | DOI:10.1016/j.antiviral.2024.105905 (Source: Antiviral Research)
Source: Antiviral Research - May 13, 2024 Category: Virology Authors: Jingbo Huang Weiqi Wang Hailun Li Yujie Bai Yumeng Song Cuicui Jiao Hongli Jin Pei Huang Haili Zhang Xianzhu Xia Feihu Yan Yuanyuan Li Hualei Wang Source Type: research

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
This study demonstrates that recombinant RABV expressing tandem RBD-heterotrimer as a multivalent immunogen could elicit a broad-spectrum immune response and potent protection against SARS-CoV-2, making it a promising candidate for future human or veterinary vaccines and offering a novel perspective in other vaccine design.PMID:38740191 | DOI:10.1016/j.antiviral.2024.105905 (Source: Antiviral Research)
Source: Antiviral Research - May 13, 2024 Category: Virology Authors: Jingbo Huang Weiqi Wang Hailun Li Yujie Bai Yumeng Song Cuicui Jiao Hongli Jin Pei Huang Haili Zhang Xianzhu Xia Feihu Yan Yuanyuan Li Hualei Wang Source Type: research

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
This study demonstrates that recombinant RABV expressing tandem RBD-heterotrimer as a multivalent immunogen could elicit a broad-spectrum immune response and potent protection against SARS-CoV-2, making it a promising candidate for future human or veterinary vaccines and offering a novel perspective in other vaccine design.PMID:38740191 | DOI:10.1016/j.antiviral.2024.105905 (Source: Antiviral Research)
Source: Antiviral Research - May 13, 2024 Category: Virology Authors: Jingbo Huang Weiqi Wang Hailun Li Yujie Bai Yumeng Song Cuicui Jiao Hongli Jin Pei Huang Haili Zhang Xianzhu Xia Feihu Yan Yuanyuan Li Hualei Wang Source Type: research

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
This study demonstrates that recombinant RABV expressing tandem RBD-heterotrimer as a multivalent immunogen could elicit a broad-spectrum immune response and potent protection against SARS-CoV-2, making it a promising candidate for future human or veterinary vaccines and offering a novel perspective in other vaccine design.PMID:38740191 | DOI:10.1016/j.antiviral.2024.105905 (Source: Antiviral Research)
Source: Antiviral Research - May 13, 2024 Category: Virology Authors: Jingbo Huang Weiqi Wang Hailun Li Yujie Bai Yumeng Song Cuicui Jiao Hongli Jin Pei Huang Haili Zhang Xianzhu Xia Feihu Yan Yuanyuan Li Hualei Wang Source Type: research

A new compound, phomaherbarine A, induces cytolytic reactivation in Epstein-Barr virus-positive B cell lines
In conclusion, these findings indicate that phomaherbarine A may be a promising candidate for therapeutic intervention in patients with EBV-associated B cell lymphomas.PMID:38735576 | DOI:10.1016/j.antiviral.2024.105906 (Source: Antiviral Research)
Source: Antiviral Research - May 12, 2024 Category: Virology Authors: So-Eun Bae Jin Won Choi Ji-Woon Hong Hyeri Ku Kyu-Young Sim Gwang-Hoon Ko Dae Sik Jang Sang Hee Shim Sung-Gyoo Park Source Type: research

A new compound, phomaherbarine A, induces cytolytic reactivation in Epstein-Barr virus-positive B cell lines
In conclusion, these findings indicate that phomaherbarine A may be a promising candidate for therapeutic intervention in patients with EBV-associated B cell lymphomas.PMID:38735576 | DOI:10.1016/j.antiviral.2024.105906 (Source: Antiviral Research)
Source: Antiviral Research - May 12, 2024 Category: Virology Authors: So-Eun Bae Jin Won Choi Ji-Woon Hong Hyeri Ku Kyu-Young Sim Gwang-Hoon Ko Dae Sik Jang Sang Hee Shim Sung-Gyoo Park Source Type: research

New Technologies in Therapeutic Antibody Development: The Next Frontier for Treating Infectious Diseases
Antiviral Res. 2024 May 9:105902. doi: 10.1016/j.antiviral.2024.105902. Online ahead of print.ABSTRACTAdaptive immunity to viral infections requires time to neutralize and clear viruses to resolve infection. Fast growing and pathogenic viruses are quickly established, are highly transmissible and cause significant disease burden making it difficult to mount effective responses, thereby prolonging infection. Antibody-based passive immunotherapies can provide initial protection during acute infection, assist in mounting an adaptive immune response, or provide protection for those who are immune suppressed or immune deficient...
Source: Antiviral Research - May 11, 2024 Category: Virology Authors: Sheila M Keating Brett W Higgins Source Type: research

Lectibodies as antivirals
Antiviral Res. 2024 May 9:105901. doi: 10.1016/j.antiviral.2024.105901. Online ahead of print.ABSTRACTGrowing concerns regarding the emergence of highly transmissible viral diseases highlight the urgent need to expand the repertoire of antiviral therapeutics. For this reason, new strategies for neutralizing and inhibiting these viruses are necessary. A promising approach involves targeting the glycans present on the surfaces of enveloped viruses. Lectins, known for their ability to recognize specific carbohydrate molecules, offer the potential for glycan-targeted antiviral strategies. Indeed, numerous studies have reported...
Source: Antiviral Research - May 11, 2024 Category: Virology Authors: Ian Santisteban Celis Nobuyuki Matoba Source Type: research